ReviewApplied microbiology and biotechnology2022
Impact of novel microbial secondary metabolites on the pharma industry.
Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 82 citations in OpenAlex.
- Bioprospecting of cultivable actinobacteria from tropical peat swamp forest soil reveals Streptomyces with potent antimicrobial activity.Antonie van Leeuwenhoek · 2026Article
- Hydrocinnamic Acid From Candida albicans: Isolation, Characterization, and Antibacterial Activity Against Multidrug-Resistant Bacteria.Biomedical chromatography : BMC · 2026Article
- Inhibitors of cytochromemBio · 2026Article
- Advances in tools, strategies, and applications of mining of microbial genomes for novel antimicrobials: a comprehensive review.Folia microbiologica · 2026Review
- In vitro and in silico analysis of the fungicidal potential of secondary metabolites from a bacterial endophyte against Botrytis cinerea.BMC biotechnology · 2026Article
- Impact of the Transcriptional Regulator SCO7424 Overexpression on Antibiotic Production inAntibiotics (Basel, Switzerland) · 2026Article
- Eco-friendly nanoparticles fromNanoscale advances · 2026Article
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Article
- Optimization, characterization and biological activity of siderophore produced by marine Streptomyces coelicolor.PloS one · 2026Article
- Mycosubtilin Induces G1 Phase Block and Autophagy in Cervical Cancer HeLa Cells.Probiotics and antimicrobial proteins · 2026Article
- Identification of widely conserved biosynthetic gene cluster involved in pigment production ofmSystems · 2025Article
- Strategies Used for the Discovery of New Microbial Metabolites with Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Review
- Genomic potential of crustose coralline algae-associated bacteria for the biosynthesis of novel antimicrobials.Microbial genomics · 2025Article
- Genome mining identifies a diversity of natural product biosynthetic capacity in human respiratorymSphere · 2025Article
- Current Approaches and Implications in Discovery of Novel Bioactive Products from Microbial Sources.Current microbiology · 2025Review
- Tracing the Origin and Evolution of the Fungal Mycophenolic Acid Biosynthesis Pathway.Genome biology and evolution · 2025Article
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Natural Source-Derived Compounds with Antifungal Activity Against Medically Relevant Fungi.Infection and drug resistance · 2025Review
- Changing the Inoculum Type From Preculture to Spore Suspension Markedly Alters the Production of Secondary Metabolites in Filamentous Microbial Coculture.Current microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Microorganisms are remarkable producers of a wide diversity of natural products that significantly improve human health and well-being. Currently, these natural products comprise half of all the pharmaceuticals on the market. After the discovery of penicillin by Alexander Fleming 85 years ago, the search for and study of antibiotics began to gain relevance as drugs. Since then, antibiotics have played a valuable role in treating infectious diseases and have saved many human lives. New molecules with anticancer, hypocholesterolemic, and immunosuppressive activity have now been introduced to treat other relevant diseases. Smaller biotechnology companies and academic laboratories generate novel antibiotics and other secondary metabolites that big pharmaceutical companies no longer develop. The purpose of this review is to illustrate some of the recent developments and to show the potential that some modern technologies like metagenomics and genome mining offer for the discovery and development of new molecules, with different functions like therapeutic alternatives needed to overcome current severe problems, such as the SARS-CoV-2 pandemic, antibiotic resistance, and other emerging diseases. KEY POINTS: • Novel alternatives for the treatment of infections caused by bacteria, fungi, and viruses. • Second wave of efforts of microbial origin against SARS-CoV-2 and related variants. • Microbial drugs used in clinical practice as hypocholesterolemic agents, immunosuppressants, and anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.